

EXHIBIT A
Attorney Docket No. 1101-220
U.S. Application Serial No. 09/079,678
Marked Version of the Claims

(Amended) A method of delivering an active agent in vivo comprising administering to a subject a [purified] composition [of claim 22] comprising a purified protein which specifically binds a gastro-intestinal tract receptor, which receptor is selected from the group consisting of HPT1 (SEQ ID NO:178), hPEPT1 (SEQ ID NO:176), D2H (SEQ ID NO:179), and hSI (SEQ ID NO:181), wherein the purified protein is bound to a material comprising an active agent, said active agent being of value in the treatment of a mammalian disease or disorder.

32. (Amended) A method of delivering a drug to a subject comprising administering to the subject a [purified] composition [of claim 30] comprising a purified protein which specifically binds a gastro-intestinal tract receptor, which receptor is selected from the group consisting of HPT1 (SEQ ID NO:178), hPEPT1 (SEQ ID NO:176), D2H (SEQ ID NO:179), and hSI (SEQ ID NO:181), wherein the purified protein is bound to a material comprising an active agent of value in the treatment of a mammalian disease or disorder, and wherein said protein is covalently bound to a particle containing a drug.

33. (Amended) A method of delivering a drug to a subject comprising administering to the subject a [purified] composition [of claim 31] comprising a purified protein which specifically binds a gastro-intestinal tract receptor, which receptor is selected from the group consisting of HPT1 (SEQ ID NO:178), hPEPT1 (SEQ ID NO:176), D2H (SEQ ID NO:179), and hSI (SEQ ID NO:181), wherein the purified protein is bound to a material comprising an active agent of value in the treatment of a mammalian disease or disorder, and wherein said protein is covalently bound to a drug.

75. (Amended) A method of delivering a drug to a subject comprising administering to the subject a therapeutically effective amount of [the] a pharmaceutical composition [of claim 80] comprising a therapeutically effective amount of a nucleic acid encoding a chimeric protein comprising (i) a first protein comprising at least 6 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NOS:1-

55, said contiguous amino acids being capable of specifically binding to a gastro-intestinal tract receptor selected from the group consisting of HPT1 (SEQ ID NO:178), hPEPT1 (SEQ ID NO:176), D2H (SEQ ID NO:179), and hSI (SEQ ID NO:181), said first protein being fused via a covalent bond to (ii) a second protein, said second protein being a drug; and a pharmaceutically acceptable carrier.